1. Home
  2. VACI vs HELP Comparison

VACI vs HELP Comparison

Compare VACI & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VACI

Viking Acquisition Corp. I Class A Ordinary Shares

N/A

Current Price

$9.93

Market Cap

310.8M

ML Signal

N/A

HELP

Cybin Inc. Common Stock

N/A

Current Price

$4.80

Market Cap

281.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VACI
HELP
Founded
2025
N/A
Country
United States
Canada
Employees
N/A
50
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
310.8M
281.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VACI
HELP
Price
$9.93
$4.80
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$95.00
AVG Volume (30 Days)
47.6K
1.1M
Earning Date
01-01-0001
07-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.86
$4.29
52 Week High
$10.07
$8.55

Technical Indicators

Market Signals
Indicator
VACI
HELP
Relative Strength Index (RSI) 47.54 42.81
Support Level $9.90 $4.47
Resistance Level $10.07 $5.02
Average True Range (ATR) 0.02 0.35
MACD -0.00 0.02
Stochastic Oscillator 42.86 46.83

Price Performance

Historical Comparison
VACI
HELP

About VACI Viking Acquisition Corp. I Class A Ordinary Shares

Viking Acquisition Corp I is a blank check company.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: